Get the Stockscreener App
2.45
15.52%
-0.45
Tuhura Biosciences Inc stock is traded at $2.45, with a volume of 278.57K.
It is down -15.52% in the last 24 hours and down -43.81% over the past month.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
See More
Previous Close:
$2.90
Open:
$2.93
24h Volume:
278.57K
Relative Volume:
0.82
Market Cap:
$103.69M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-32.88%
1M Performance:
-43.81%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.42
$3.0027
1-Week Range:
$2.42
$3.63
52-Week Range:
$2.42
$7.20
Tuhura Biosciences Inc Stock (HURA) Company Profile
Name
Tuhura Biosciences Inc
Sector
Industry
Phone
813-875-6600
Address
10500 UNIVERSITY CENTER DR., TAMPA
Compare HURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
2.45 | 103.69M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-05-24 | Initiated | Maxim Group | Buy |
Tuhura Biosciences Inc Stock (HURA) Latest News
TuHURA Biosciences (HURA) to Release Earnings on Wednesday - Defense World
TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - Milton Daily Standard
Apollon Wealth Management LLC Invests $253,000 in TuHURA Biosciences (NASDAQ:HURA) - MarketBeat
TuHURA Biosciences: A Hold On Only The Faintest Glimmers Of Efficacy (NASDAQ:HURA) - Seeking Alpha
TuHURA Biosciences secures $3M through warrant exercises By Investing.com - Investing.com Australia
TuHURA Biosciences secures $3M through warrant exercises - Investing.com India
Equities Analysts Offer Predictions for HURA Q2 Earnings - MarketBeat
TuHURA Biosciences (HURA) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Research Analysts Issue Forecasts for HURA Q2 Earnings - Defense World
TuHURA Biosciences’ Acquisition of Kineta - Global Legal Chronicle
HURA: Initiating an Immune Response - Yahoo Finance
TuHURA Biosciences (NASDAQ:HURA) Trading Down 2.6%Here's Why - MarketBeat
TuHURA Biosciences (NASDAQ:HURA) Trading Down 2.6% – Here’s What Happened - Defense World
TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC - ACCESS Newswire
When Will TuHURA Biosciences, Inc. (NASDAQ:HURA) Turn A Profit? - Simply Wall St
When Can We Expect A Profit From TuHURA Biosciences, Inc. (NASDAQ:HURA)? - Yahoo Finance
Analyzing Enveric Biosciences (NASDAQ:ENVB) and TuHURA Biosciences (NASDAQ:HURA) - Defense World
Rep. Laurel M. Lee Purchases Shares of TuHURA Biosciences (NASDAQ:HURA) - Defense World
Rep. Laurel M. Lee Buys TuHURA Biosciences (NASDAQ:HURA) Shares - MarketBeat
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of TuHURA Biosciences, Inc.HURA - The Eastern Progress Online
TuHURA Biosciences appoints new accounting firm By Investing.com - Investing.com Australia
TuHURA Biosciences appoints new accounting firm - Investing.com India
TuHURA Biosciences (NASDAQ:HURA) Upgraded to "Strong-Buy" at RODMAN&RENSHAW - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHYF, ML, HURA, KANT on Behalf of Shareholders - Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHYF, ML, HURA, KANT on Behalf of Shareholders - Finansavisen
H.C. Wainwright sets $11 target on HURA with buy rating - Investing.com
Cancer Immunotherapy: TuHURA Biosciences to Acquire Kineta - orrick.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PDCO, ML, HURA, KANT on Behalf of Shareholders - Finansavisen
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ML, PDCO, HURA, KANT on Behalf of Shareholders - GlobeNewswire
TuHURA Biosciences, Inc. entered into a non-binding agreement to acquire Kineta, Inc. from Craig Philips and others for $30 million. - Marketscreener.com
TuHURA Biosciences to Acquire Kineta - citybiz
HURA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of TuHURA Biosciences, Inc. Is Fair to Shareholders - The Bakersfield Californian
TuHURA Biosciences to Acquire Kineta, Inc. in 2025 - TipRanks
Kineta Merges with TuHURA to Enhance Cancer Treatment - TipRanks
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc. - Sacramento Bee
TuHURA to acquire Kineta in immunotherapy push - Investing.com
TuHURA to acquire Kineta in immunotherapy push By Investing.com - Investing.com UK
TuHURA Biosciences to Acquire Kineta, Adding Promising Phase 2 Cancer Immunotherapy to Pipeline - StockTitan
Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024 - The Eastern Progress Online
Tuhura Biosciences Inc Stock (HURA) Financials Data
There is no financial data for Tuhura Biosciences Inc (HURA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):